Dr. Samuel J. White
Chief Executive Officer
PhD Applied ImmunologyHon. Assoc. Prof., NottinghamDiagnostics PioneerMedTech Government Advisor
Applied immunologist and geneticist. Chief Executive Officer. Former Associate Professor at York St John University and Director for the Centre of Innovation. Former Senior Lecturer at Nottingham Trent University. Honorary Associate Professor of Translational Immunology at the University of Nottingham. PhD in Applied Immunology. Over 15 years of experience in translational research, diagnostics development, and One Health innovation.
Dr White oversees scientific, regulatory, and operational strategy across the Group. He has led major programmes in translational research, diagnostics development, and One Health innovation, working with partners including the FEI, Chester Zoo, and Universität Bern.
He has held senior academic roles, contributed to high-impact research outputs, advised government and international bodies, and co-founded several biotechnology and health innovation companies.
Research focus: Immunodiagnostic assay development, subunit and mRNA vaccine technologies, lateral-flow and point-of-care diagnostics, recombinant protein engineering, test optimisation for clinical and field environments.
Media: Science communicator for The Times, The Telegraph, BBC, and BBC Radio 4.
Patent holder for multiplex lateral flow technology capable of detecting 20–60 analytes simultaneously, and for a plaster-format microneedle diagnostic device. A global leading scientist in bone health research.
Wilson PB, White SJ et al. "Genomic characterisation of bioaerosols within livestock facilities." Science of The Total Environment, Vol. 918, March 2024. DOI: 10.1016/j.scitotenv.2024.170722
FEI-funded study. Long-read Nanopore sequencing identified as the unmet methodological standard across 29 eligible studies for bioaerosol characterisation, validating HH Global Holdings' genomic pipeline as the scientific frontier.
"You also won't meet ever someone like Sam, he can do the fundamental science and with a mind's eye to the future know how that can translate into something commercially, whilst having a trigger to 'go' or 'no' without having the depth of understanding that Sam has. To be able to do that, from a funded startup through to two patents, that's unheard of."
— Prof Philippe B. Wilson, Executive Chairman
Whether you need diagnostic platform development, expert evidence services, preclinical drug development, or a full laboratory setup, we'd welcome the opportunity to discuss your requirements.